To develop a covalent modifier for the amyloid-forming protein β-2-microglobulin (magenta), researchers used a nanobody (teal ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

The Company's discovery platform combines rational drug design with radiochemistry to create novel small molecule radioligands that overcome current limitations in radiopharmaceutical development. Its ...

Metal-organic frameworks were the next big thing in chemistry when they were invented more than three decades ago. Now, these intriguing materials are becoming commercial tools for capturing carbon ...

Previous studies have demonstrated that self-assembly of metabolite amyloid-like fibrils can be inhibited by small molecules that are bona fide inhibitors of proteinaceous amyloids such as NQTrp, ...

Serine was also targeted in the identification of inhibitors of plasma kallikrein using boronate-containing molecules. Stocks and colleagues used molecular docking of non-covalent compounds into the ...